Trial record 1 of 39 for:
teach azithromycin
Testing the Effect of Adding Chronic Oral Azithromycin to Inhaled Tobramycin in People With Cystic Fibrosis (CF) (TEACH)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02677701 |
|
Recruitment Status :
Completed
First Posted : February 9, 2016
Results First Posted : March 1, 2021
Last Update Posted : June 28, 2021
|
Sponsor:
Seattle Children's Hospital
Collaborators:
National Heart, Lung, and Blood Institute (NHLBI)
Cystic Fibrosis Foundation
CF Therapeutics Development Network Coordinating Center
Information provided by (Responsible Party):
David Nichols, MD, Seattle Children's Hospital
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Brief Summary:
This is a study to examine the effect of combining chronic oral azithromycin with inhaled tobramycin in adolescent and adult subjects with cystic fibrosis who are chronically infected with P. aeruginosa.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Cystic Fibrosis | Drug: azithromycin Drug: placebo (for azithromycin) Drug: inhaled tobramycin | Phase 4 |
This study is a prospective, randomized, double-blinded, placebo-controlled trial of azithromycin 500mg taken orally thrice weekly vs. placebo in subjects with cystic fibrosis and chronic airway infection with P. aeruginosa who are utilizing chronic inhaled tobramycin therapy. It will include approximately 120 subjects able to complete a primary 6-week study phase. Subjects will be at least 12 years old with a baseline forced expiratory volume at one second (FEV1) between 25-100% predicted. Subjects will continue to use clinically prescribed inhaled tobramycin cycled on/off every 4 weeks. They will be provided over-encapsulated azithromycin 500mg tablets or placebo during the primary study phase. An optional extension phase will be offered to all subjects completing the primary 6-week study. This 8-week extension phase will include an initial 4 weeks without use of inhaled tobramycin or other inhaled antibiotics, followed by a 4-week period with inhaled tobramycin use. All subjects participating in the extension phase of the study will be provided azithromycin 500mg tablets to be taken thrice weekly for the entire 8-week period.
This study will investigate how use of chronic oral azithromycin affects some of the previously demonstrated benefits to health when using inhaled tobramycin. The primary measurements will focus on lung function. Additional measurements will focus on disease-related quality of life as reported by subjects in the trial. Exploratory outcomes, including measurements of safety, are also planned.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 119 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
| Primary Purpose: | Treatment |
| Official Title: | TEACH Trial: Testing the Effect of Adding CHronic Azithromycin to Inhaled Tobramycin. A Randomized, Placebo-controlled, Double-blinded Trial of Azithromycin 500mg Thrice Weekly in Combination With Inhaled Tobramycin |
| Actual Study Start Date : | October 21, 2016 |
| Actual Primary Completion Date : | February 13, 2020 |
| Actual Study Completion Date : | February 13, 2020 |
Resource links provided by the National Library of Medicine
MedlinePlus Genetics related topics:
Cystic fibrosis
MedlinePlus related topics:
Cystic Fibrosis
Drug Information available for:
Tobramycin
Tobramycin sulfate
Azithromycin
Azithromycin dihydrate
Azithromycin monohydrate
| Arm | Intervention/treatment |
|---|---|
|
Active Comparator: azithromycin
azithromycin 500mg tablet over-encapsulated to match placebo in appearance, taken by mouth thrice weekly for 6 weeks
|
Drug: azithromycin
500mg tablet over-encapsulated to match placebo
Other Name: Zithromax Drug: inhaled tobramycin clinically prescribed inhaled tobramycin used by subjects participating in the study |
|
Placebo Comparator: placebo
encapsulated placebo taken by mouth thrice weekly for 6 weeks
|
Drug: placebo (for azithromycin) Drug: inhaled tobramycin clinically prescribed inhaled tobramycin used by subjects participating in the study |
Primary Outcome Measures :
- Relative Change in Lung Function [ Time Frame: baseline (week 0) to week 6 (6 week period) ]Relative change in FEV1 volume (L) from enrollment at week 0 to the end of the 4-week period with inhaled tobramycin at week 6
Secondary Outcome Measures :
- Relative Change in Lung Function [ Time Frame: week 2 to week 6 (4 week period) ]Relative change in FEV1 (L) from the beginning of the 4-week period with inhaled tobramycin at week 2 to the end of the 4-week period with inhaled tobramycin at week 6
- Change in Cystic Fibrosis Respiratory Symptom Diary - Chronic Respiratory Infection Symptom Score (CFRSD-CRISS) [ Time Frame: baseline (week 0) to week 6 (6 week period) ]Absolute change in CFRSD-CRISS from enrollment at week 0 to the end of the 4-week period with inhaled tobramycin at week 6. The Cystic Fibrosis Respiratory Symptoms Diary asks a participant to state the extent of 8 respiratory symptoms: difficulty breathing, feverishness, tiredness, chills or sweats, coughing, coughing up mucus, tightness in the chest, and wheezing. Each respiratory symptom is assigned a score from 0-4 based on the response, with zero corresponding to the absence of the symptom and four corresponding to symptom being present "a great deal" or "extremely." A summed score (ranging from 0-24) is calculated for each participant and converted to a final score with a range of 0 to 100, where lower scores indicate improvement of symptoms.
- Change in Cystic Fibrosis Questionnaire - Revised Respiratory Symptom Score (CFQ-R RSS) [ Time Frame: baseline (week 0) to week 6 (6 week period) ]Absolute change in the CFQ-R RSS from enrollment at week 0 to the end of the 4-week period with inhaled tobramycin at week 6. Age appropriate versions of Cystic Fibrosis Questionnaire - Revised ask a participant from 4 to 6 questions related to respiratory symptoms. The Respiratory Domain Scaled Score is calculated as follows: 100*[sum of {responses-1}] / [{number of responses}*3] only if [number of responses] ≥ [number of possible responses]/2; otherwise the score is set to missing. The scaled score ranges from 0 to 100 and higher scores indicate improvement of symptoms.
Other Outcome Measures:
- Change in Sputum Pseudomonas Aeruginosa Bacterial Density [ Time Frame: baseline (week 0) to week 6 (6 week period) ]Absolute change in log10 transformed quantitative Pseudomonas aeruginosa (Pa) bacterial density as measured by colony forming units (CFUs) per mL of sputum from enrollment at week 0 to the end of the 4-week period with inhaled tobramycin at week 6. Culture results below the lower limit of detection of 1x10^2 were set to 1/2 of that LLD prior to log transformation.
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 12 Years and older (Child, Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- 12 years old or older
- documented diagnosis of cystic fibrosis
- written informed consent (and assent when applicable)
- at least two respiratory cultures growing P. aeruginosa within the last 12 months
- FEV1% predicted between 25-100%
- use of at least two cycles of inhaled tobramycin within the last 24 weeks
- Off TISP and other inhaled anti-pseudomonal antibiotics for at least 2 weeks at Visit 1 and remain off of any inhaled antibiotics for an additional 2 weeks before starting inhaled tobramycin
- most recent liver function test results less than 4 times the upper limit of normal, obtained within the last 12 months
- prior or current use of azithromycin for at least four consecutive weeks
- stable clinical status and therapeutic regimen
Exclusion Criteria:
- weight <40 kg
- positive pregnancy test, lactating, or unwillingness to practice a pre-defined form of contraception, which includes abstinence
- inability to perform reproducible spirometry
- inability or unwillingness to cycle off of inhaled tobramycin for one 4-week period and without use of any additional inhaled antibiotics
- respiratory culture with Burkholderia cepacia complex species within 24 months or with nontuberculous mycobacteria within 18 months of screening
- use of intravenous or oral anti-pseudomonal antibiotics within 4 weeks of screening
- use of investigational therapy within 4 weeks of screening
- use of systemic corticosteroids equivalent to a daily dose more than 10mg of prednisone
- use of nelfinavir, warfarin, haloperidol, or methadone (concern of drug interaction with azithromycin)
- initiation of cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapy within 30 days
- ECG abnormality at screening requiring prompt further medical attention, or QTc interval >480 msec for males and >486 msec for females
- any other condition that, in the opinion of the site investigator, would compromise the safety of the subject or quality of the data
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02677701
Locations
Show 39 study locations
Sponsors and Collaborators
Seattle Children's Hospital
National Heart, Lung, and Blood Institute (NHLBI)
Cystic Fibrosis Foundation
CF Therapeutics Development Network Coordinating Center
Investigators
| Principal Investigator: | David P Nichols, MD | National Jewish Health |
Study Documents (Full-Text)
Documents provided by David Nichols, MD, Seattle Children's Hospital:
Documents provided by David Nichols, MD, Seattle Children's Hospital:
Study Protocol [PDF] June 11, 2018
Statistical Analysis Plan [PDF] February 1, 2017
| Responsible Party: | David Nichols, MD, Associate Professor of Pediatrics, Seattle Children's Hospital |
| ClinicalTrials.gov Identifier: | NCT02677701 |
| Other Study ID Numbers: |
TEACH-IP-15 1R01HL124053-01A1 ( U.S. NIH Grant/Contract ) NICHOL15A0 ( Other Grant/Funding Number: Cystic Fibrosis Foundation Therapeutics ) |
| First Posted: | February 9, 2016 Key Record Dates |
| Results First Posted: | March 1, 2021 |
| Last Update Posted: | June 28, 2021 |
| Last Verified: | June 2021 |
Additional relevant MeSH terms:
|
Azithromycin Cystic Fibrosis Fibrosis Pathologic Processes Pancreatic Diseases Digestive System Diseases Lung Diseases |
Respiratory Tract Diseases Genetic Diseases, Inborn Infant, Newborn, Diseases Tobramycin Anti-Bacterial Agents Anti-Infective Agents |